HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.

AbstractOBJECTIVES:
To assess the renal and non-renal efficacy of mycophenolate mofetil (MMF) in Japanese patients with systemic lupus erythematosus (SLE).
METHODS:
We conducted a retrospective study to assess the renal and non-renal efficacies of MMF in Japanese patients with systemic lupus erythematosus (SLE). We analyzed 14 patients with lupus nephritis (LN) who were given MMF, and 13 patients who received monthly intravenous cyclophosphamide (IVCY) as induction therapy, and a further 19 patients without LN who were treated with MMF, and 13 patients who took tacrolimus (TAC) to reduce glucocorticoid dosages. We assessed the therapeutic effects of each therapeutic regime on renal and non-renal disease manifestations over a six-month period after treatment initiation.
RESULTS:
Median urine protein to creatinine ratios in the MMF and IVCY groups significantly decreased from 2.2 to 0.7 g/gCr and from 3.3 to 0.5 g/gCr, respectively. Significant improvements in serum immunological variables (serum complements C3 and C4 and the anti-double stranded DNA antibody) and reductions in the SLE disease activity index (SLEDAI) and daily prednisolone dosages were observed in each group with LN. MMF and TAC significantly improved SLEDAI and serum immunological variables and reduced daily prednisolone dosages in patients without LN.
CONCLUSION:
The present results demonstrated that MMF might be an effective treatment for renal and non-renal manifestations in Japanese patients with SLE and has potential as a good therapeutic alternative and steroid-sparing agent.
AuthorsMai Kawazoe, Kaichi Kaneko, Zento Yamada, Shotaro Masuoka, Satoshi Mizutani, Soichi Yamada, Kotaro Shikano, Hiroshi Sato, Makoto Kaburaki, Sei Muraoka, Shinichi Kawai, Toshihiro Nanki
JournalClinical rheumatology (Clin Rheumatol) Vol. 38 Issue 6 Pg. 1571-1578 (Jun 2019) ISSN: 1434-9949 [Electronic] Germany
PMID30778862 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Antinuclear
  • Cyclophosphamide
  • Prednisolone
  • Mycophenolic Acid
  • Tacrolimus
Topics
  • Administration, Intravenous
  • Adult
  • Antibodies, Antinuclear (blood)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Japan
  • Kidney Function Tests
  • Lupus Erythematosus, Systemic (drug therapy)
  • Lupus Nephritis (drug therapy)
  • Male
  • Middle Aged
  • Mycophenolic Acid (administration & dosage, adverse effects)
  • Prednisolone (administration & dosage)
  • Retrospective Studies
  • Tacrolimus (administration & dosage, adverse effects)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: